Tyvaso DPI is a prostacyclin mimetic indicated for the treatment of:
• Pulmonary arterial hypertension (PAH; WHO Group 1) to improve
exercise ability. Studies with Tyvaso establishing effectiveness
predominately included patients with NYHA Functional Class III
symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH
associated with connective tissue diseases (33%).
• Pulmonary hypertension associated with interstitial lung disease
(PH-ILD; WHO Group 3) to improve exercise ability. The study with
Tyvaso establishing effectiveness predominately included patients with
etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of
idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and
emphysema (CPFE) (25%), and WHO Group 3 connective tissue
disease (22%).
